Trial ID or NCT#





A research study using a method of treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors.

Official Title

Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Maximilian Diehn, MD, PhD
Radiation oncologist
Assistant Professor of Radiation Oncology (Radiation Therapy)
Quynh-Thu Le, MD, FACR, FASTRO
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology-Head and Neck Surgery
Billy W. Loo, Jr., MD, PhD, DABR
Radiation oncologist, Thoracic specialist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Peter G Maxim

Contact us to find out if this trial is right for you.


Rachel Freiberg
(650) 725-0438